|
CA3105045A1
|
|
Loadable porous structures for use as implants
|
|
US2021113664A1
|
|
Implants for release of lipophilic or amphiphilic pharmaceutical substances
|
|
WO2018067882A1
|
|
Implantable devices for drug delivery with reduced burst release
|
|
CA2846402A1
|
|
Methods and device for treating opioid addiction
|
|
KR20130038840A
|
|
Heterogeneous implantable devices for drug delivery
|
|
WO2007139744A2
|
|
Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
|
|
CN101374532A
|
|
Use of gallium to treat biofilm-associated infectons
|
|
EP1945273A1
|
|
Treatment and prevention of adverse liver conditions using gallium
|
|
WO2006063242A1
|
|
Methods and compositions for induction of tumor regression
|
|
CA2526101A1
|
|
Implantable polymeric device for sustained release of nalmefene
|
|
CN1777426A
|
|
Implantable polymeric device for sustained release of dopamine agonist
|
|
CA2492175A1
|
|
Combination of chemotherapeutic drugs for increasing antitumor activity
|
|
NZ536965A
|
|
Nonerodible polymeric matrix with buprenorphine encapsulated for the treatment of opiate addiction and pain
|
|
US7115256B1
|
|
Methods of treating schizophrenia
|
|
EP1044024A1
|
|
Use of pigmented retinal epithelial cells for creation of an immune privilege site
|
